Myelodysplastic Syndromes (MDS): Recent Updates and Evolving Treatment Paradigms

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.

Panelists review the presented patient profile and shares how they would have approached treatment.

Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.

The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.

Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.